Phase I/II trial of taxol [paclitaxel], ifosfamide, and cisplatin for cisplatin-resistant germ cell tumor patients with favorable prognostic features.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary) ; Cisplatin; Filgrastim; Ifosfamide
- Indications Germ cell cancer; Ovarian cancer; Testicular cancer
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Jan 2003) added as reported by ClinicalTrials.gov.
- 27 Sep 2005 New trial record.